de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7:220–33.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA: A Cancer Journal for Clinicians. 2021;71:7–33.

White JF, Noinaj N, Shibata Y, et al. Structure of the agonist-bound neurotensin receptor. Nature. 2012;490:508–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, Martinez-Fong D, Trédaniel J, Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne). 2012;3:184.

PubMed  Google Scholar 

Goedert M, Reeve JG, Emson PC, Bleehen NM. Neurotensin in human small cell lung carcinoma. Br J Cancer. 1984;50:179–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302–9.

Article  CAS  PubMed  Google Scholar 

Mazella J, Vincent J-P. Functional roles of the NTS2 and NTS3 receptors. Peptides. 2006;27:2469–75.

Article  CAS  PubMed  Google Scholar 

Ehlers RA, Bonnor RM, Wang X, Hellmich MR, Evers BM. Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery. 1998;124:239–47.

Article  PubMed  Google Scholar 

Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun. 2000;269:704–8.

Article  CAS  PubMed  Google Scholar 

Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C. Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells. Int J Cancer. 2007;120:1652–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Christou N, Blondy S, David V, et al. Neurotensin pathway in digestive cancers and clinical applications: an overview. Cell Death Dis. 2020;11:1–12.

Article  Google Scholar 

Ouyang Q, Zhou J, Yang W, Cui H, Xu M, Yi L. Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin Exp Pharmacol Physiol. 2017;44:841–6.

Article  CAS  PubMed  Google Scholar 

Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011;93:1369–78.

Article  CAS  PubMed  Google Scholar 

Ocejo-Garcia M, Ahmed SI, Coulson JM, Woll PJ. Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer. 2001;33:1–9.

Article  CAS  PubMed  Google Scholar 

Younes M, Wu Z, Dupouy S, et al. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. Oncotarget. 2014;5:8252–69.

Article  PubMed  PubMed Central  Google Scholar 

Alifano M, Souazé F, Dupouy S, et al. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010;16:4401–10.

Article  CAS  PubMed  Google Scholar 

Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides. 2001;22:109–15.

Article  CAS  PubMed  Google Scholar 

Reubi JC, Waser B, Friess H, Büchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate. 1997;31:183–92.

Article  CAS  PubMed  Google Scholar 

Souazé F, Dupouy S, Viardot-Foucault V, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006;66:6243–9.

Article  PubMed  Google Scholar 

Maoret JJ, Pospaï D, Rouyer-Fessard C, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun. 1994;203:465–71.

Article  CAS  PubMed  Google Scholar 

Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL. Novel bioactive and Stable Neurotensin Peptide Analogues Capable of Delivering Radiopharmaceuticals and Molecular beacons to tumors. J Med Chem. 2003;46:3403–11.

Article  CAS  PubMed  Google Scholar 

Bergmann R, Scheunemann M, Heichert C, et al. Biodistribution and catabolism of 18F-labeled neurotensin (8–13) analogs. Nucl Med Biol. 2002;29:61–72.

Article  CAS  PubMed  Google Scholar 

Teodoro R, Faintuch BL, Núñez EGF, Queiróz RG. Neurotensin (8–13) analogue: radiolabeling and biological evaluation using different chelators. Nucl Med Biol. 2011;38:113–20.

Article  CAS  PubMed  Google Scholar 

Buchegger F, Bonvin F, Kosinski M, et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003;44:1649–54.

CAS  PubMed  Google Scholar 

Zhang K, An R, Gao Z, Zhang Y, Aruva MR. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8–13. Nucl Med Biol. 2006;33:505–12.

Article  CAS  PubMed  Google Scholar 

García-Garayoa E, Bläuenstein P, Blanc A, Maes V, Tourwé D, Schubiger PA. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2009;36:37–47.

Article  PubMed  Google Scholar 

de Visser M, Janssen PJJM, Srinivasan A, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–9.

Article  PubMed  Google Scholar 

Wu Z, Liu S, Nair I, et al. 64Cu labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 receptor expression. Theranostics. 2014;4:770–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, Li L, Liu S, et al. Facile Preparation of a thiol-reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin receptor-positive tumor. J Nucl Med. 2014;55:1178–84.

Article  CAS  PubMed  Google Scholar 

Deng H, Wang H, Wang M, Li Z, Wu Z. Synthesis and evaluation of 64Cu-DOTA-NT-Cy5.5 as a dual-modality PET/Fluorescence probe to Image Neurotensin receptor-positive tumor. Mol Pharm. 2015;12:3054–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alshoukr F, Prignon A, Brans L, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem. 2011;22:1374–85.

Article  CAS  PubMed  Google Scholar 

Deng H, Wang H, Zhang H, et al. Imaging neurotensin receptor in prostate Cancer with 64Cu-Labeled neurotensin analogs. Mol Imaging. 2017;16:1536012117711369.

Article  PubMed  PubMed Central  Google Scholar 

Gully D, Canton M, Boigegrain R, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A. 1993;90:65–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Myers RM, Shearman JW, Kitching MO, Ramos-Montoya A, Neal DE, Ley SV. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem Biol. 2009;4:503–25.

Article  CAS  PubMed  Google Scholar 

Gully D, Labeeuw B, Boigegrain R, et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997;280:802–12.

CAS  PubMed  Google Scholar 

Betancur C, Canton M, Burgos A, et al. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. Eur J Pharmacol. 1998;343:67–77.

Article  CAS  PubMed  Google Scholar 

Schaeffer P, Laplace MC, Bernat A, et al. SR142948A is a potent antagonist of the cardiovascular effects of neurotensin. J Cardiovasc Pharmacol. 1998;31:545–50.